VALN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Valneva SE (VALN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show bearish trends, analysts have mixed to negative views with recent downgrades, and there are no significant positive catalysts or trading signals. The stock's uncertain path to approval for its Lyme disease vaccine and lack of recent financial or congressional trading data further add to the uncertainty. A hold position is recommended until more clarity or positive developments emerge.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 40.775, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 5.167 and resistance at 5.776.
Jefferies maintains a Buy rating with a $15 price target, citing potential approval path for the Lyme disease vaccine despite recent trial results.
Goldman Sachs downgraded the stock to Sell with a $4.90 price target, citing multiple data disappointments and an uncertain path to approval for the Lyme disease vaccine. The stock has bearish technical indicators and no recent positive news.
No financial data available for analysis.
Analysts are mixed to negative. Goldman Sachs downgraded the stock to Sell, Guggenheim lowered the price target to $11 but maintained a Buy rating, and Jefferies reiterated a Buy rating with a $15 price target.
